Herpes Zoster Rates Are Increasing, but Why?Herpes Zoster Rates Are Increasing, but Why?

The idea that varicella vaccination beginning in 1996 is the cause of an increase in shingles cases is not supported by the evidence. CDC Expert Commentary
Source: Medscape Infectious Diseases Headlines - Category: Infectious Diseases Tags: Infectious Diseases Commentary Source Type: news

Related Links:

Shingles is becoming less common in both adults and children in the U.S., according to results from a database study.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
(MedPage Today) -- Vaccine development may help with prevention of herpes zoster in this population
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
This report evaluates the fifth year of the shingles vaccination programme in England from 2017 to 2018.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
hon Varicella-zoster virus (VZV) is a pathogenic human herpes virus that causes varicella (chickenpox) as a primary infection, following which it becomes latent in peripheral ganglia. Decades later, the virus may reactivate either spontaneously or after a number of triggering factors to cause herpes zoster (shingles). Varicella and its complications are more severe in the immunosuppressed. The most frequent and important complication of VZV reactivation is postherpetic neuralgia, the cause of which is unknown and for which treatment is usually ineffective. Reactivation of VZV may also cause a wide variety of neurologic...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
AbstractThe herpes zoster (shingles) vaccine is recommended for all adults aged ≥ 60 years without contraindications to prevent shingles and post-herpetic neuralgia. There are no published studies on zoster vaccination rates, barriers, or workflows in adults who have experienced homelessness. Due to barriers specific to this vaccine, including difficulty determining insura nce coverage, high upfront costs, need for storage in a freezer, and under-prescription by physicians, uptake is lower compared to other recommended vaccines for older adults. To address these barriers, we developed a new approach of partn...
Source: Journal of Community Health - Category: International Medicine & Public Health Source Type: research
This article discusses new vaccination recommendations for herpes zoster.
Source: Journal of the American Academy of Physician Assistants - Category: Primary Care Tags: Pharmacology Consult Source Type: research
Abstract As primary care providers and experts on diseases affecting the skin, such as herpes zoster (shingles) and human papillomavirus-related cancers, dermatologists are often asked to make important recommendations on vaccines and vaccinations; however, a rise in antivaccine attitudes-sometimes referred to as "vaccine hesitancy"-among patient populations, especially in North America and Europe, has created new challenges for the practicing dermatologist. Here we provide a brief overview of some of the major evidence that refutes commonly held misperceptions about vaccines. PMID: 30207522 [PubMed - in process]
Source: Skinmed - Category: Dermatology Authors: Tags: Skinmed Source Type: research
CONCLUSIONS: ZVL reduced the risk of shingles among an elderly population. Given the negative impact of shingles and PHN on QoL, the benefits of vaccination are clear. Improving uptake in the UK is needed in this population. PMID: 30195489 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
About one-third of the US population will develop herpes zoster (HZ, commonly known as shingles) over a lifetime, while two-thirds will not. It is not clear exactly why certain people are susceptible to HZ; however, we may be coming closer to an answer. In this issue of the JCI, a study by Levin et al. provides important details concerning pathogenesis of and protection from HZ. The authors characterized differences in the immunologic responses induced by two HZ vaccines, the live attenuated zoster vaccine (ZV) and the more recently developed adjuvanted varicella-zoster virus (VZV) glycoprotein E (gE) subunit herpes zoster...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Just one in five patients with inflammatory bowel disease (IBD) who are eligible for the herpes zoster (HZ) vaccine actually receive it, according to new study in VA patients.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
More News: Herpes | Infectious Diseases | Shingles | Shingles (Herpes Zoster) Vaccine | Vaccines | Varicella-Zoster Virus Vaccine